The mixed Q4 financial results for Amphastar Pharmaceuticals likely disappointed investors, leading to a decrease in stock price. Mixed results often indicate that while some financial metrics met or exceeded expectations, others fell short, causing uncertainty about the company's short-term financial health and growth prospects.